---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-298526"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2026-07-08T20:05:33+00:00"
generated_at: "2026-07-08T20:06:07.308854+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# GSK terminates collaboration with Alector after Phase 3/2 failures; loan repaid

## Summary
- GSK provided notice terminating the collaboration agreement for latozinemab and nivisnebart, effective Jan 2, 2027.
- Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN missed co-primary endpoint (Oct 2025); Phase 2 PROGRESS-AD of nivisnebart discontinued (Apr 2026).
- Alector repaid $10.4M principal plus interest and fees to Hercules Capital, terminating the loan agreement on July 8, 2026.

## SEC filing metadata
- accession: 0001193125-26-298526
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2026-07-08T20:05:33+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000119312526298526/0001193125-26-298526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000119312526298526/alec-20260706.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-298526
- JSON: https://secwatch.observer/filing/0001193125-26-298526.json
- Plain text: https://secwatch.observer/filing/0001193125-26-298526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.